Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143996 · ClinicalTrials.gov registry record · Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML), sponsored by Cullinan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT05143996 is a Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 60 participants, below the 89-participant average among 17 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (33% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT05143996, a Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by Cullinan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Conditions Studied
Interventions
- DRUG CLN-049
Study Locations (11)
Florida
- University of Miami Health System - Miami
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
- New York University - New York
Alabama
- University of Alabama O'Neal Cancer Center - Birmingham
California
- UCLA - Los Angeles
Georgia
- Emory University Hospital - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- Duke Cancer Center - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05143996
The ClinicalTrials.gov registry entry for NCT05143996 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 17 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (33% lower). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndrome (MDS) appearing as the primary indexed condition, and to 1 intervention - of which CLN-049 is the first listed.
NCT05143996 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Florida, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT05143996 about?
NCT05143996 is a clinical study titled "CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)". CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
What is the current status of trial NCT05143996?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-11-18. Estimated completion is 2027-06.
What conditions does trial NCT05143996 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome (MDS), Relapsed/Refractory Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT05143996?
The interventions under investigation include: CLN-049 (DRUG).
Who is sponsoring clinical trial NCT05143996?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143996 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RECRUITING · Phase 1
-
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
RECRUITING · Phase 1
-
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
ACTIVE NOT RECRUITING · Phase 1
-
Improving Blood Stem Cell Collection and Transplant Procedures
COMPLETED · Phase 1
Explore more on PlainTrial
Myelodysplastic Syndrome (MDS)
All registered trials for this condition
Relapsed/Refractory Acute Myeloid Leukemia (AML)
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.